| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Isoxanthohumol does not have a single defined molecular target but exerts its effects through multiple mechanisms. It has been shown to suppress viral replication through interference with redox and signaling pathways. The compound modulates host immune responses by activating antiviral defense genes. Its antiproliferative effects are mediated through cell cycle arrest and induction of apoptosis. The compound also exhibits anti-inflammatory activity by modulating inflammatory signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, isoxanthohumol has been shown to inhibit proliferation of B16 and A375 melanoma cells with IC50 values of 22.15 and 22.9 μM, respectively, in MTT assays. The compound slows cell division and induces apoptosis in melanoma cells. Isoxanthohumol suppresses viral replication through interference with redox and signaling pathways. It also modulates host immune responses through activation of antiviral defense genes. These activities contribute to its potential as a chemopreventive agent.
|
| ln Vivo |
In vivo, isoxanthohumol has been studied for its potential chemopreventive and therapeutic activities. The compound has demonstrated anti-inflammatory effects in animal models. Its anti-angiogenic properties suggest potential applications in cancer prevention and treatment. Isoxanthohumol has been reported to have apparent chemotherapeutic prevention activity. Further in vivo studies are ongoing to evaluate its therapeutic potential in various disease models.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for isoxanthohumol are not typically performed as the compound is a natural product with pleiotropic effects. However, binding studies with various targets have been conducted to elucidate its mechanism of action. These include assays for antioxidant activity (e.g., DPPH radical scavenging, ORAC), anti-inflammatory activity (e.g., inhibition of COX-2, iNOS), and antiproliferative activity (e.g., inhibition of cell cycle regulators). Standard biochemical assays are used for these evaluations.
|
| Cell Assay |
In vitro cellular studies are conducted using various cancer cell lines including melanoma (B16, A375) and other cancer types. Cells are treated with isoxanthohumol at various concentrations (typically μM ranges) for defined time periods. Cell viability is assessed using MTT or CellTiter-Glo assays. Apoptosis is measured by Annexin V/PI staining or caspase-3 activity assays. Anti-inflammatory activity is evaluated in immune cells by measuring cytokine production and inflammatory marker expression.
|
| Animal Protocol |
In vivo animal experiments are performed using xenograft or inflammation models. Tumor-bearing or inflammation-induced mice are administered isoxanthohumol via oral gavage or intraperitoneal injection at various doses. Tumor volume or inflammation markers are measured over time. Endpoints include tumor growth inhibition, survival, and histopathological examination. Pharmacodynamic studies evaluate the compound's effects on redox status, inflammatory markers, and angiogenesis in target tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of isoxanthohumol include solubility in DMF (3 mg/ml), DMSO (2.5 mg/ml), ethanol (3 mg/ml), and DMSO:PBS (1:3) at 0.25 mg/ml. The compound has a molecular weight of 354.40 g/mol, λmax of 289 nm, and appears as a crystalline solid. It is a polyphenol found in Humulus lupulus. Storage at -20°C is recommended. The compound should be protected from light and moisture.
|
| Toxicity/Toxicokinetics |
Toxicological data for isoxanthohumol are derived from preclinical studies. As a natural compound from hops, it is generally considered to have low toxicity. However, high doses may cause adverse effects. The compound is for research use only and not intended for human therapeutic applications. Standard safety precautions should be followed when handling the compound. No significant acute toxicity has been reported at effective doses in animal studies.
|
| References | |
| Additional Infomation |
Isoxanthohumol is a type of flavanone compound. It has been reported that Isoxanthohumol is found in hops, Streptomyces, and Sophora flavescens, and relevant data are available for reference.
Isoxanthohumol is also known as IX and IXN. It is a natural, prenylated chalcone isolated from hops (Humulus lupulus). The compound has diverse biological activities including antiproliferative, anti-inflammatory, antiviral, antioxidant, and anti-angiogenic properties. It is supplied as an analytical standard with ≥95-98% purity and is used in research on cancer prevention, inflammation, and viral infections. |
| Molecular Formula |
C21H22O5
|
|---|---|
| Molecular Weight |
354.39600
|
| Exact Mass |
354.147
|
| CAS # |
521-48-2
|
| Related CAS # |
(2S)-Isoxanthohumol;70872-29-6
|
| PubChem CID |
513197
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.321
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
519
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=CCC1=C2C(=C(C=C1O)OC)C(=O)CC(O2)C3=CC=C(C=C3)O)C
|
| InChi Key |
YKGCBLWILMDSAV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H22O5/c1-12(2)4-9-15-16(23)10-19(25-3)20-17(24)11-18(26-21(15)20)13-5-7-14(22)8-6-13/h4-8,10,18,22-23H,9,11H2,1-3H3
|
| Chemical Name |
7-hydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~141.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: 2.5 mg/mL (7.05 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8217 mL | 14.1084 mL | 28.2167 mL | |
| 5 mM | 0.5643 mL | 2.8217 mL | 5.6433 mL | |
| 10 mM | 0.2822 mL | 1.4108 mL | 2.8217 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
